Ardent Health (NYSE:ARDT) Reaches New 52-Week Low – Here’s What Happened

Ardent Health, Inc. (NYSE:ARDT)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.21 and last traded at $8.2750, with a volume of 200957 shares trading hands. The stock had previously closed at $8.46.

Key Headlines Impacting Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Negative Sentiment: Several national plaintiff firms say a securities class action has been filed alleging Ardent misled investors about revenue recognition systems and reserves after the company’s poor Q3 2025 results; the notice highlights a prior ~33% share plunge tied to the results. Ardent Health (ARDT) Facing Securities Class Action Amid Receivables and Reserves Issues Driving 33% Plunge – Hagens Berman
• Negative Sentiment: Bleichmar Fonti & Auld (BFA) has filed a securities fraud class action and is notifying investors of alleged misstatements about collectability of receivables; the firm urges affected investors to review the complaint and consider participation. ARDT INVESTORS: BFA Law Notifies Ardent Health Investors…
• Negative Sentiment: Multiple plaintiff firms (Schall, Robbins Geller, Faruqi, Rosen, Glancy and others) are soliciting lead‑plaintiff candidates and reminding investors of the March 9, 2026 deadline — increasing the momentum and coordination risk of consolidated litigation. ARDT Investors Have Opportunity to Lead Ardent Health Inc Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Investor alerts from several firms (Robbins Geller, Rosen, Glancy, Faruqi, etc.) underscore broad legal interest; that raises the likelihood of settlements, indemnity/reserve needs, and lengthy litigation — all potential negative earnings/ cash‑flow implications. INVESTOR ALERT: Ardent Health Inc (ARDT) Investors Have Opportunity to Lead Class Action – Robbins Geller

Analysts Set New Price Targets

Several research firms have recently issued reports on ARDT. JPMorgan Chase & Co. lowered their price target on Ardent Health from $12.00 to $11.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th. Mizuho decreased their target price on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Bank of America dropped their target price on shares of Ardent Health from $12.00 to $10.00 and set an “underperform” rating on the stock in a research note on Thursday, November 13th. The Goldman Sachs Group initiated coverage on shares of Ardent Health in a research report on Tuesday, October 14th. They set a “neutral” rating and a $19.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ardent Health in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.58.

Ardent Health Stock Performance

The firm has a market cap of $1.19 billion, a P/E ratio of 5.71, a P/E/G ratio of 4.96 and a beta of 0.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.95 and a current ratio of 2.08. The business’s 50-day simple moving average is $8.83 and its 200 day simple moving average is $11.50.

Ardent Health (NYSE:ARDT) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. As a group, equities analysts predict that Ardent Health, Inc. will post 1.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Ardent Health by 103.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company’s stock worth $194,000 after purchasing an additional 7,182 shares during the period. Goldman Sachs Group Inc. increased its position in Ardent Health by 1,684.9% in the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock worth $10,558,000 after buying an additional 724,841 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Ardent Health by 235.1% in the first quarter. Jane Street Group LLC now owns 57,468 shares of the company’s stock worth $790,000 after buying an additional 40,318 shares during the period. Acadian Asset Management LLC raised its stake in shares of Ardent Health by 574.9% in the first quarter. Acadian Asset Management LLC now owns 40,238 shares of the company’s stock worth $550,000 after buying an additional 34,276 shares during the period. Finally, CWM LLC lifted its position in shares of Ardent Health by 990.6% during the 2nd quarter. CWM LLC now owns 2,203 shares of the company’s stock valued at $30,000 after buying an additional 2,001 shares in the last quarter.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.